Epizyme Inc - Company Profile

All the data and insights you need on Epizyme Inc in one report.

$295

Buy Report View Sample

Save hours of research time and resources with
our up-to-date Epizyme Inc Strategy Report
Understand Epizyme Inc position in the market,
performance and strategic initiatives.
Gain competitive edge and increase your
chances of success

Epizyme Inc: Premium Databases

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 8 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	11 Jan 2018	Lorem
Epizyme selects CRO MedPace for Phase II registration-directed cancer basket trial of tazemetostat – source	06 Jun 2017	Alaric DeArment
Epizyme’s Phase I/II tazemetostat likely to improve NHL response rates, but draws skepticism as aggressive DLBCL option – experts	27 Jan 2017	Alaric DeArment
Oryzon eyes Nasdaq IPO YE16 or early 2017 with potential mezzanine round prior – CEO	14 Sep 2015	Natalie Morrison

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Epizyme Inc and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Contact the team or request a demo to find out how our data can drive your business forward